Share on StockTwits

Repligen Corp. (NASDAQ:RGEN)’s share price reached a new 52-week high during trading on Friday , Stock Ratings News reports. The stock traded as high as $24.34 and last traded at $23.91, with a volume of 211,103 shares. The stock had previously closed at $23.77.

RGEN has been the subject of a number of recent research reports. Analysts at Zacks downgraded shares of Repligen Corp. to a “neutral” rating in a research note on Monday, June 30th. They now have a $23.80 price target on the stock. Separately, analysts at Janney Montgomery Scott initiated coverage on shares of Repligen Corp. in a research note on Thursday, June 26th. They set a “buy” rating and a $26.00 price target on the stock. Finally, analysts at Jefferies Group raised their price target on shares of Repligen Corp. from $20.00 to $22.00 in a research note on Wednesday, June 4th. They now have a “buy” rating on the stock.

The stock has a 50-day moving average of $21.01 and a 200-day moving average of $16.33. The company has a market cap of $770.5 million and a price-to-earnings ratio of 42.52.

Repligen Corp. (NASDAQ:RGEN) last released its earnings data on Thursday, May 8th. The company reported $0.13 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.07 by $0.06. The company had revenue of $16.33 million for the quarter, compared to the consensus estimate of $15.14 million. Repligen Corp.’s revenue was down .8% compared to the same quarter last year. On average, analysts predict that Repligen Corp. will post $0.29 earnings per share for the current fiscal year.

In other Repligen Corp. news, Director Thomas F. Ryan, Jr. sold 10,000 shares of the stock on the open market in a transaction that occurred on Friday, June 27th. The shares were sold at an average price of $22.41, for a total value of $224,100.00. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Repligen Corporation is a United States-based life sciences company focused on the development, production and commercialization of products used in the process of manufacturing biological drugs.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.